<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814368</url>
  </required_header>
  <id_info>
    <org_study_id>CLNA043A12203</org_study_id>
    <nct_id>NCT04814368</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)</brief_title>
  <official_title>A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will establish safety and efficacy of canakinumab and LNA043 in patients with knee&#xD;
      osteoarthritis (OA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2021</start_date>
  <completion_date type="Anticipated">April 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking only applies to the canakinumab treatment. LNA043 treatment is open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cartilage volume in the index region measured by MRI</measure>
    <time_frame>Baseline to Day 197</time_frame>
    <description>Comparing LNA043 with no LNA043 treatment (Placebo) arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain subscale</measure>
    <time_frame>Baseline to Day 85</time_frame>
    <description>Comparing canakinumab with no canakinumab treatment (Placebo) arms.&#xD;
The KOOS questionnaire is a commonly used instrument to assess the patient's perception about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-LNA043 antibodies in serum</measure>
    <time_frame>Day 15, 43, 85, 197 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANGPTL3 serum concentrations</measure>
    <time_frame>Day 1, 15, 43, 85, 197 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ANGPTL3 synovial fluid concentrations</measure>
    <time_frame>Day 1, 15, 43 and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LNA043 PK profile in serum (Cmax)</measure>
    <time_frame>Day 1 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LNA043 PK profile in serum (Tmax)</measure>
    <time_frame>Day 1 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LNA043 PK profile in serum (AUC)</measure>
    <time_frame>Day 1 and 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cartilage volume of the index region measured by MRI</measure>
    <time_frame>Baseline to Day 197 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cartilage thickness of the index region measured by MRI</measure>
    <time_frame>Baseline to Day 197 and 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in synovitis level measured from Ktrans by Dynamic Contrast Enhanced MRI (DCE-MRI)</measure>
    <time_frame>Baseline to Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in numeric rating scale (NRS) Pain over time</measure>
    <time_frame>Baseline to Day 15, 29, 43, 57, 71 and 85</time_frame>
    <description>The Numerical Rating Scale (NRS) Pain is a subjective assessment in which individuals rate their pain on an eleven-point numerical scale. The scale ranges from 0 (no pain) to 10 (worst possible pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscale over time</measure>
    <time_frame>Baseline to Day 15, 29, 43, 57, 71 and 85</time_frame>
    <description>The KOOS questionnaire is a commonly used instrument to assess the patient's perception about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) Function in daily living (ADL) subscale over time</measure>
    <time_frame>Baseline to Day 15, 29, 43, 57, 71 and 85</time_frame>
    <description>The KOOS questionnaire is a commonly used instrument to assess the patient's perception about their knee and associated problems. The original KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QoL) (4 questions). On this scale, 100% indicates no problems and 0% indicates extreme problems.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to canakinumab + LNA043</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to canakinumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab + LNA043</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>canakinumab + LNA043</description>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>canakinumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>intra-articular injection (into the knee)</description>
    <arm_group_label>canakinumab</arm_group_label>
    <arm_group_label>canakinumab + LNA043</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LNA043</intervention_name>
    <description>intra-articular injection (into the knee)</description>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_label>canakinumab + LNA043</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo to canakinumab</intervention_name>
    <description>intra-articular injection (into the knee)</description>
    <arm_group_label>LNA043</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe OA pain (corresponding to NRS Pain ≥5 to ≤9) in the target knee for&#xD;
             the majority of days in the last 3 months prior to Screening&#xD;
&#xD;
          -  KOOS pain subscale &lt;60 for the target knee at Screening 1 and at Day 1&#xD;
&#xD;
          -  High sensitivity C-reactive Protein (hsCRP) ≥2 mg/L&#xD;
&#xD;
          -  Radiographic KL grade 2 or 3 knee OA and joint space width (JSW) 2-4 mm (men) or&#xD;
             1.5-3.5 mm (women) in the medial tibiofemoral compartment (TFC) in the target knee&#xD;
&#xD;
          -  Contrast-enhanced MRI (CE-MRI) diagnosed moderate or severe knee synovitis based on an&#xD;
             established synovititis scoring system (moderate score 9-12 or severe score ≥13)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of, or planned; knee replacement (partial or total) in either knee;&#xD;
             arthroscopy or lavage of the target knee within 6 months prior to screening; any other&#xD;
             previous surgical intervention in the target knee, including mosaicplasty,&#xD;
             microfracture, meniscectomy &gt;50% or osteotomy&#xD;
&#xD;
          -  Moderate to severe pain in the contralateral knee for the majority of days in the last&#xD;
             3 months prior to screening&#xD;
&#xD;
          -  Malalignment &gt;7.5° in the target knee (either varus or valgus)&#xD;
&#xD;
          -  Any diagnosis of inflammatory arthritis or connective tissue disease (e.g. rheumatoid&#xD;
             arthritis, psoriatic arthritis, ankylosing spondylitis, gout, Paget's disease,&#xD;
             systemic lupus erythematosus) or other systemic condition that might confound&#xD;
             assessment of OA&#xD;
&#xD;
          -  Ipsilateral hip OA or hip prosthesis recently implanted (within 1 year prior to&#xD;
             screening) or hip replacement on either side planned within the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <state>Czech Republic</state>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolin</city>
        <zip>280 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>canakinumab</keyword>
  <keyword>LNA043</keyword>
  <keyword>knee</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>OA</keyword>
  <keyword>joint pain</keyword>
  <keyword>cartilage</keyword>
  <keyword>MRI</keyword>
  <keyword>DCE-MRI</keyword>
  <keyword>KOOS</keyword>
  <keyword>NRS Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the study in line with applicable laws and regulations.&#xD;
This study data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

